Levi & Korsinsky, LLP
CLASS ACTION UPDATE for SPCE, ATHA and LOTZ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 15, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
SPCE Shareholders Click Here: https://www.zlk.com/pslra-1/virgin-galactic-holdings-inc-loss-submission-form?prid=17667&wire=1
ATHA Shareholders Click Here: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17667&wire=1
LOTZ Shareholders Click Here: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=17667&wire=1
* ADDITIONAL INFORMATION BELOW *To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Virgin Galactic Holdings, Inc. (NYSE:SPCE)
SPCE Lawsuit on behalf of: investors who purchased October 26, 2019 - April 30, 2021
Lead Plaintiff Deadline: July 27, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/virgin-galactic-holdings-inc-loss-submission-form?prid=17667&wire=1
According to the filed complaint, during the class period, Virgin Galactic Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) for accounting purposes, Social Capital Hedosophia Holdings Corp.'s ("SCH") warrants were required to be treated as liabilities rather than equities; (ii) Virgin Galactic had deficient disclosure controls and procedures and internal control over financial reporting; (iii) as a result, the Company improperly accounted for SCH warrants that were outstanding at the time of the business combination; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Athira Pharma, Inc. (NASDAQ:ATHA)
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline : August 24, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17667&wire=1
According to the filed complaint, (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
CarLotz, Inc. (NASDAQ:LOTZ)
LOTZ Lawsuit on behalf of: investors who purchased December 30, 2020 - May 25, 2021
Lead Plaintiff Deadline : September 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=17667&wire=1
According to the filed complaint, during the class period, CarLotz, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) as a result, the Company's gross profit per unit would be negatively impacted; (3) to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
iZafe Group14.10.2021 20:31:56 CEST | Press release
The Price for Dosell Consumer is Communicated
iZafe Group14.10.2021 14:28:43 CEST | Press release
Launch of Dosell Consumer in Italy
TECO 2030 ASA14.10.2021 09:58:48 CEST | Press release
TECO 2030 Signs Supply Frame Agreement with Chemgas Shipping
iZafe Group14.10.2021 09:41:43 CEST | Press release
Launch of Dosell Consumer in Italy
NanoViricides, Inc. 13.10.2021 12:46:57 CEST | Press release
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
iZafe Group13.10.2021 09:21:42 CEST | Press release
Completion of Patents to International Markets
Physitrack13.10.2021 08:21:38 CEST | Press release
Invitation to Physitrack PLC Q3 Interim Report 2020/2021 Webcast Conference
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom